Reuters /
Stringer
|
For the first time ever,
Chinese scientists report having successfully edited human embryos’ genomes.
The breakthrough has, however, also revived heated debate about the ethical
feasibility of such experiments, which are feared to lead to eugenics.
The
16-person team of researchers was based at the Sun Yat-Sen University in
Guangzhou, China, and led by Junjiu Huang, a gene-function researcher. They
tried to find out if they could cure the gene defect that causes beta-thalassemia
(a genetic blood disorder that could lead to severe anemia, poor growth,
skeletal abnormalities and even death), by editing the germ line.
RT.com report continues:
For
that purpose they used a gene-editing technique based on injecting embryos with
a complex, which consists of a protective DNA element obtained from bacteria
and a specific protein.
The
scientific team used only “non-viable” embryos obtained from local fertility
clinics, “which were abnormal and could not develop in a baby,” Huang noted.
The
open results of the study were published in the online Journal Protein &
Cell after two international scientific Journals – English Nature and American
Science – had refused to publish it due to the ethical reasons, Huang said.
Some
experts say that an embryo gene editing technique could have a bright future as
it could help to eradicate devastating genetic diseases before the baby is even
born.
Others
worry that such technology is unethical and even dangerous, because it can
wreak unknown havoc on the human genome, which is heritable. This also might
open a slippery slope to unsafe use of the technique.
"I
believe this is the first report of this gene-modifying technique applied to
human pre-implantation embryos and as such the study is a landmark, as well as
a cautionary tale," George Daley, a stem-cell biologist at Harvard Medical
School in Boston, comment on the results of the Chinese research.
"Their
study should be a stern warning to any practitioner who thinks the technology
is ready for testing to eradicate disease genes," he told Nature.
“The
ubiquitous access to and simplicity of creating such DNA and protein complex
creates opportunities for scientists in any part of the world to do any kind of
experiments they want,” Edward Lanphier, president of Sangamo Biosciences in
Richmond, California, says.
“It
underlines what we said before: we need to pause this research and make sure we
have a broad-based discussion about which direction we’re going here," he
adds, as quoted by Nature.
Ethics
is not the only concern of the researchers. According to Nature, the Chinese
team admits its results reveal serious obstacles to using this technique in
medical practice, and the problem lies in the nature of the method.
The
DNA and protein complex, which is used in the research, is programmed to target
a specific problematic gene, which is then replaced or repaired by another
molecule introduced at the same time. Such method is based on successful tests
on adult human cells and animal embryos.
However,
after injecting 86 embryos and testing 54 of the 71 surviving the researchers
found that genomes of only 28 had been successfully edited. Such low success
rates are likely to mean that the procedure cannot be used in medicine.
"If
you want to do it in normal embryos, you need to be close to 100 percent,"
Huang told Nature. "That's why we stopped. We still think it's too
immature."
In
addition, the gene-editing also affected other parts of the genome, leading to
its mutation. In case of human embryos such “unprogrammed changes” were much
more frequent than in previous experiments on adult human cells and animal
embryos.
Huang
notes that his team likely only detected a subset of the unintended mutations
because their study looked only at a portion of the genome, and not a whole
one, according to Nature.
Meanwhile, new rumors claim
at least four groups in China are conducting research in the field of gene
modification without unveiling the nature of their work. And MIT Technology
Review claims that also one US genetics centre is doing similar work, but
keeping it secret.
No comments:
Post a Comment